Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disulfiram + Copper in mCRPC
NCT02963051Phase 1Terminated
- Start
- Jul 2017
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of disulfiram in prostate cancer (PCa) (3 arms). Primary endpoint: Number of adverse events up to 2 years. Started Jul 2017; status: terminated.
02
Drugs
disulfiram
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02963051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02963051.